Barclays PLC Raises Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Barclays PLC raised its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 143.4% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 187,629 shares of the company’s stock after purchasing an additional 110,535 shares during the quarter. Barclays PLC owned 0.22% of Syndax Pharmaceuticals worth $3,612,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of SNDX. Y Intercept Hong Kong Ltd lifted its holdings in shares of Syndax Pharmaceuticals by 319.4% during the third quarter. Y Intercept Hong Kong Ltd now owns 81,302 shares of the company’s stock worth $1,565,000 after purchasing an additional 61,916 shares during the period. Two Sigma Advisers LP lifted its stake in Syndax Pharmaceuticals by 7.7% during the 3rd quarter. Two Sigma Advisers LP now owns 669,352 shares of the company’s stock valued at $12,885,000 after acquiring an additional 48,100 shares during the period. Sphera Funds Management LTD. increased its stake in shares of Syndax Pharmaceuticals by 25.9% in the third quarter. Sphera Funds Management LTD. now owns 1,034,846 shares of the company’s stock worth $19,921,000 after acquiring an additional 212,799 shares during the period. State Street Corp raised its holdings in shares of Syndax Pharmaceuticals by 4.1% during the third quarter. State Street Corp now owns 3,770,826 shares of the company’s stock worth $72,588,000 after purchasing an additional 148,491 shares during the last quarter. Finally, Stifel Financial Corp acquired a new position in Syndax Pharmaceuticals during the third quarter valued at $327,000.

Syndax Pharmaceuticals Stock Up 1.8 %

Shares of NASDAQ SNDX opened at $13.08 on Monday. Syndax Pharmaceuticals, Inc. has a 52-week low of $12.75 and a 52-week high of $25.34. The company’s 50-day simple moving average is $17.30 and its 200-day simple moving average is $19.25. The firm has a market cap of $1.12 billion, a price-to-earnings ratio of -3.60 and a beta of 0.86.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.13) by $0.15. The firm had revenue of $12.50 million during the quarter, compared to analyst estimates of $9.16 million. During the same quarter in the previous year, the firm posted ($0.73) earnings per share. Equities research analysts anticipate that Syndax Pharmaceuticals, Inc. will post -2.39 EPS for the current fiscal year.

Analyst Ratings Changes

SNDX has been the topic of several analyst reports. Citigroup increased their price target on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a research report on Tuesday, November 19th. JPMorgan Chase & Co. lifted their price target on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the company an “overweight” rating in a research report on Thursday, November 21st. HC Wainwright restated a “buy” rating and issued a $51.00 price objective on shares of Syndax Pharmaceuticals in a research report on Tuesday, December 10th. UBS Group assumed coverage on shares of Syndax Pharmaceuticals in a report on Thursday, October 24th. They set a “buy” rating and a $37.00 target price for the company. Finally, The Goldman Sachs Group increased their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $36.90.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).